Dateline: Portland, Oregon (PORTLAND, Ore.) | Fri, 08 Nov 2013
freeNewsArticles Story Summary: “Biopharmaceutical company Paragon BioTeck, Inc. today announced that it plans to launch its new line of products, known as Ilast(R), at the Annual American Academy of Ophthalmology meeting in New Orleans. Paragon signed an exclusive distribution agreement with Horus Pharma to supply Ilast(R) ocular care products in the U.S. last month, and the company is excited to release these products to ophthalmology professionals.”
ARTICLE:
Biopharmaceutical company Paragon BioTeck, Inc. today announced that it plans to launch its new line of products, known as Ilast(R), at the Annual American Academy of Ophthalmology meeting in New Orleans. Paragon signed an exclusive distribution agreement with Horus Pharma to supply Ilast ocular care products in the U.S. last month, and the company is excited to release these products to ophthalmology professionals.
Ilast is a scientifically-formulated line of lid care and ocular hygiene products designed to support the health of the eye and the tissue that surrounds it. Ilast is free from preservatives, thus eliminating many of the allergenic and cytotoxic properties that often cause irritation to the delicate skin around the eye. Ilast products are manufactured using a patented process known as Epifree(R) Technology.
This process uses low-temperature sterilization to maximize the effectiveness of active ingredients while simultaneously maintaining the microbiological integrity of the product.
About the Annual American Academy of Ophthalmology:
The American Academy of Ophthalmology is the most expansive association of eye care providers, including osteopathic doctors, medical doctors and ophthalmologists in existence. The Academy works to support the professional interests of eye care providers, as well as to promote continuing education and lifelong enrichment.
At the Academy’s annual meeting, eye care professionals can attend educational sessions, view exhibits and learn about the newest developments in the field of ophthalmology. This year’s meeting is scheduled to take place from November 16 to November 19, 2013.
About Paragon BioTeck, Inc.:
Paragon BioTeck is a privately-held, ophthalmic-focused biopharmaceutical and medical device company pursuing the development and commercialization of products addressing unmet medical needs in the fight to protect and preserve eyesight.
For more information on the company and its work, visit http://www.paragonbioteck.com/ .
###
Copyright © 2013 by Paragon BioTeck, Inc. and Send2Press® Newswire, a service of Neotrope® – all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.
• Web Image (72dpi): https://www.send2press.com/mediaboom/13-1108-ilast_400x300.jpg
• Media Contact Information: https://www.send2press.com/mediadrome/2013-11-1108-001.txt
• Story Title: Paragon Puts Ilast Center Stage
• REFERENCE KEYWORDS/TERMS: Ilast ocular care, Portland, Oregon, Epifree Technology, Ophthalmology and Vision, Medical, Pharma, PORTLAND, Ore..
IMPORTANT NOTICE: some content which is considered “old” or “archival” may reference an event which has already occurred; some content possibly considered “advertorial” may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Paragon BioTeck, Inc.); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Fri, 08 Nov 2013 17:19:12 GMT].
USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
NEWS SOURCE: Paragon BioTeck, Inc. :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by Send2Press® Newswire, a service of Neotrope®.